Top 10 Advances Impacting Clinical Practice in Hematological Malignancies With updates from ASCO 2017 and ASH 2017

Edward Stadtmauer, MD, Section Chief, Hematological Malignancies at the Abramson Center, examines advances in immunotherapy for adult multiple myeloma (MM), acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) as reported at ASCO 2017 and ASH 2016. In this wide-ranging discussion, Dr. Stadtmauer reviews separate studies in pembrolizumab/pom/dex therapy, anti-B-cell maturation antigen (BCMA) therapy, and BCMA-directed chimeric antigen T-cell (CART-BCMA) therapy for relaped/refractory MM.

Related Links:



November 17, 2017

Created by

Penn Physician VideoLink